Satsuma Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference

SOUTH SAN FRANCISCO, Calif., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced that John Kollins, its President and Chief Executive Officer, will participate in a Fireside Chat at the 5^th Annual Evercore ISI HealthCONx Conference, which is being held virtually November 29 - December 1.